For decades, doctors reached for opioids for moderate to severe pain. Then the addiction crisis hit, and everything changed. The pain management market report by MRFR shows that chronic pain is the largest application, but neuropathic pain is the fastest‑growing. The market is $75.23 billion and will hit $134.05 billion by 2035, growing at 5.39% CAGR. Why the shift? Because we're finally treating pain without creating addicts.

What's driving growth? Pharmacological treatment is still the largest segment, but interventional procedures (nerve blocks, spinal cord stimulation) are the fastest‑growing. The pain management market analysis highlights that oral administration is the largest route, but injectable is the fastest‑growing — especially for biologics and monoclonal antibodies that target pain at its source.

What's new? Non‑opioid medications like CGRP antagonists for migraine and NGF inhibitors for osteoarthritis. Also, digital therapeutics — apps that teach pain coping skills, backed by clinical trials.

The bottom line: pain is complex, and there's no magic bullet. But the market is finally moving away from opioids. If you're in pain, ask your doctor about non‑opioid options. They might work just as well — without the risk.